Corvus Pharmaceuticals Inc
CRVS7.600USD
-0.220-2.81%
收盘 11/07, 16:00（美东）报价延迟15分钟
567.58M总市值
亏损市盈率 TTM
关于 Corvus Pharmaceuticals Inc 公司
Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发 ITK 抑制剂，作为一系列癌症和免疫疾病的免疫疗法的新方法。其主要候选产品是索奎替尼，一种选择性共价 ITK（白细胞介素 2 诱导性 T 细胞激酶）抑制剂，目前正在对患有各种复发性恶性 T 细胞淋巴瘤的患者进行多中心 1/1b 期临床试验。索奎替尼旨在抑制某些恶性 T 细胞的增殖。其第二个候选产品 ciforadenant 是一种口服的腺苷 A2A 受体小分子拮抗剂，旨在通过阻断肿瘤微环境中的免疫抑制腺苷与 A2A 受体的结合来禁用肿瘤破坏免疫系统攻击的能力。该公司的第三个候选产品是穆帕多利单抗，一种人源化单克隆抗体，旨在与 CD73 上的特定位点发生反应。
Corvus Pharmaceuticals Inc简介
公司代码CRVS
公司名称Corvus Pharmaceuticals Inc
上市日期Mar 23, 2016
CEODr. Richard A. Miller, M.D.
员工数量31
证券类型Ordinary Share
年结日Mar 23
公司地址863 Mitten Rd Ste 102
城市BURLINGAME
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94010-1311
电话16509004520
网址https://www.corvuspharma.com/
公司代码CRVS
上市日期Mar 23, 2016
CEODr. Richard A. Miller, M.D.
Corvus Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. William B. Jones, Ph.D.
Dr. William B. Jones, Ph.D.
Senior Vice President - Pharmaceutical Development
Senior Vice President - Pharmaceutical Development
--
--
Mr. Richard van Den Broek
Mr. Richard van Den Broek
Independent Director
Independent Director
--
--
Mr. David Moore
Mr. David Moore
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
4.84%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
其他
67.10%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
4.84%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
其他
67.10%
股东类型
持股股东
占比
Private Equity
18.22%
Investment Advisor
13.86%
Hedge Fund
11.23%
Investment Advisor/Hedge Fund
8.66%
Individual Investor
3.95%
Venture Capital
2.99%
Research Firm
1.01%
Pension Fund
0.20%
Bank and Trust
0.09%
其他
39.79%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
186
42.32M
56.66%
+2.43M
2025Q2
154
41.04M
53.29%
-590.66K
2025Q1
158
41.01M
55.15%
-1.27M
2024Q4
137
42.04M
65.42%
+8.08M
2024Q3
112
32.95M
52.86%
+765.53K
2024Q2
108
30.52M
48.98%
-5.02M
2024Q1
116
20.23M
41.14%
-8.66M
2023Q4
119
21.51M
43.96%
-7.95M
2023Q3
129
21.52M
44.20%
-7.79M
2023Q2
132
21.81M
46.84%
-8.41M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
7.17M
9.62%
+221.35K
+3.19%
Jun 30, 2025
Point72 Asset Management, L.P.
7.04M
9.45%
+4.25M
+152.63%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.62M
4.85%
+2.65M
+274.72%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.4%
+786.56K
+31.54%
Jun 30, 2025
Adams Street Partners, LLC
3.28M
4.4%
--
--
Jun 30, 2025
RTW Investments L.P.
2.68M
3.6%
--
--
Jun 30, 2025
Miller (Richard A)
2.32M
3.12%
+559.07K
+31.66%
May 07, 2025
Vivo Capital, LLC
2.23M
3%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
1.73M
2.32%
+150.00K
+9.49%
Jun 30, 2025
Perceptive Advisors LLC
1.44M
1.93%
+1.44M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.25%
Invesco NASDAQ Future Gen 200 ETF
0.62%
Tema Oncology ETF
0.55%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
Proshares Ultra Russell 2000
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.25%
Invesco NASDAQ Future Gen 200 ETF
占比0.62%
Tema Oncology ETF
占比0.55%
iShares Micro-Cap ETF
占比0.08%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.05%
iShares Biotechnology ETF
占比0.04%
iShares Russell 2000 Growth ETF
占比0.03%
Proshares Ultra Russell 2000
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
